How do analysts view PFE's earnings trajectory for next year?

Analysts have a positive outlook on Pfizer's (PFE) earnings trajectory for next year, as reflected by the consensus rating and price target. 1. **Consensus Rating**: The consensus rating for Pfizer is "Strong Buy," indicating that analysts believe the stock has the potential for further price appreciation. This rating is based on analysts' opinions and market conditions, and it suggests that the majority of analysts have a bullish view of the company's future performance. 2. **Price Target**: The average current price target for Pfizer is $30.33, which represents a significant upside potential from the current price of $24.29. This price target suggests that analysts are expecting the stock to perform well in the near term, potentially driven by factors such as the company's financial performance, market conditions, and industry trends.